# Enable Injections

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enable-injections

- Industry: Medical Devices & Equipment
- Headquarters: Cincinnati, US
- Website: www.enableinjections.com
- Total disclosed funding: $206M
- Latest round: Series C (Jan 27, 2022)
- Investors on record: 12

## About

Enable Injections, Inc. specializes in innovative drug delivery solutions with its enFuse platform, designed to facilitate convenient subcutaneous administration of medications, particularly for oncology patients. Founded in 2010 and headquartered in Ohio, US, Enable Injections, Inc. focuses on the development of its enFuse platform for drug delivery. The company has undergone a strategic pivot towards partnerships with pharmaceutical companies to enhance its market presence. Mike Hooven leads as CEO and has a history of entrepreneurship in health technology. In January 2022, the company raised USD 150.04 mn in Series C funding, led by Magnetar Capital, with participation from multiple investors including Cincinnati Children's Hospital Medical Center. This funding supports the company’s ongoing growth and product development efforts, bringing the total amount raised to USD 150.04 mn.Enable Injections specializes in the development and manufacturing of the enFuse, an innovative wearable drug delivery platform that allows for the subcutaneous administration of large volumes of medication. This hands-free technology enables patients to receive their treatments through simple site injections under the skin, enhancing convenience and comfort. The enFuse platform addresses the needs of patients requiring ongoing medication, particularly in oncology, and has been recognized for its advanced capabilities. The products are marketed primarily in North America and Europe, with ongoing partnerships for clinical trials and commercial launches.Enable Injections generates revenue through strategic collaborations with pharmaceutical partners for the development and commercialization of their enFuse technology. The company operates a partnership model, engaging with clients who provide medications compatible with the enFuse platform. Revenue is structured around joint agreements that may include shared revenue from sales of therapies utilizing the enFuse injector. Specific pricing plans are not disclosed, but the revenue model aligns with traditional B2B transactions as well as direct-to-consumer scenarios for ongoing patient needs. In January 2026, Enable Injections, Inc. raised USD 30 million in venture funding from returning investor Sanofi. The company will use the January 2026 funding to support its product innovation and manufacturing capabilities.

## Funding rounds

- Series C, Jan 27, 2022, $150M — GCM Grosvenor, Ohio Innovation Fund, Magnetar Capital, CincyTech, Cincinnati Children's Hospital Medical Center, Cintrifuse Capital, Squarepoint, Woody Creek Capital Partners
- Series B, Oct 22, 2018, $31M — Ohio Innovation Fund, CincyTech, Cincinnati Children's Hospital Medical Center, Sanofi, Cintrifuse Capital, ORI Capital, Cleveland Clinic Ventures
- Series A, Nov 17, 2016, $15M — Ohio Innovation Fund, CincyTech, Cintrifuse Capital, ORI Capital
- Series A, Aug 26, 2016, $10M — ORI Capital
- Seed, Jun 1, 2011 — Partisan Management Group

## Investors

- Partisan Management Group (https://capitalatlas.ai/funds/partisan-management-group) — Seed
- ORI Capital (https://capitalatlas.ai/funds/ori-capital) — Series A, Series B
- Ohio Innovation Fund (https://capitalatlas.ai/funds/ohio-innovation-fund) — Series A, Series B, Series C
- CincyTech (https://capitalatlas.ai/funds/cincytech) — Series A, Series B, Series C
- Cintrifuse Capital (https://capitalatlas.ai/funds/cintrifuse-capital) — Series A, Series B, Series C
- Cincinnati Children's Hospital Medical Center — Series B, Series C
- Sanofi — Series B
- Cleveland Clinic Ventures (https://capitalatlas.ai/funds/cleveland-clinic-ventures) — Series B
- GCM Grosvenor — Series C
- Magnetar Capital (https://capitalatlas.ai/funds/magnetar-capital) — Series C
- Squarepoint — Series C
- Woody Creek Capital Partners — Series C